PBS updates

Coralan (Ivabradine)

ivabradine 5 mg tablet, 56 · ORAL · PBS code 10012Y

STREAMLINED

What it costs

AU$31.03 PBS-determined price per 56 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2013-12-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic heart failure


Patient must be symptomatic with NYHA classes II or III; AND

Patient must be in sinus rhythm; AND

Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; AND

Patient must have a resting heart rate at or above 77 bpm at the time ivabradine treatment is initiated; AND

Patient must receive concomitant optimal standard chronic heart failure treatment, which must include the maximum tolerated dose of a beta-blocker, unless contraindicated or not tolerated.

Resting heart rate should be measured by ECG or echocardiography, after 5 minutes rest.

The ECG or echocardiography, result must be documented in the patient's medical records when treatment is initiated.

Sponsor: Servier Laboratories (Aust.) Pty. Ltd. ABN 54 004 838 500

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.